To determine if the EGFR tyrosine kinase inhibitor erlotinib could cause hypomagnesemia irritation and cardiac tension erlotinib was administered to rats (10 mg/kg/time) for 9 weeks. erlotinib-induced hypomagnesemia as much as 42%; decreased circulating SP suppressed neutrophil superoxide activity and 8-isoprostane elevations; cardiac nitrotyrosine was reduced. Echocardiography revealed minor to moderately reduced still left ventricular… Continue reading To determine if the EGFR tyrosine kinase inhibitor erlotinib could cause